Get the Stockscreener App
3.45
0.86%
-0.03
Pre-market:
3.48
0.03
+0.87%
Ardelyx Inc stock is traded at $3.45, with a volume of 3.23M.
It is down -0.86% in the last 24 hours and down -7.75% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$3.48
Open:
$3.47
24h Volume:
3.23M
Relative Volume:
0.75
Market Cap:
$890.75M
Revenue:
$427.68M
Net Income/Loss:
$-58.06M
P/E Ratio:
-14.48
EPS:
-0.2382
Net Cash Flow:
$-37.50M
1W Performance:
+2.07%
1M Performance:
-7.75%
6M Performance:
-35.51%
1Y Performance:
-43.90%
1-Day Range:
$3.415
$3.49
1-Week Range:
$3.33
$3.63
52-Week Range:
$3.33
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
3.45 | 890.75M | 427.68M | -58.06M | -37.50M | -0.2382 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-03-25 | Resumed | Raymond James | Strong Buy |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Levi & Korsinsky Urges Ardelyx, Inc. (ARDX) Shareholders to Act Before Lead Plaintiff Deadline November 16, 2026 - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming DeadlinesARDX - PR Newswire
ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’ - Stocktwits
Portnoy Law Firm Announces Class Action on Behalf of Ardelyx, Inc. Investors - GlobeNewswire
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Ardelyx, Inc. LawsuitARDX - PR Newswire
ARDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Class Action Lawsuit Filed: Ardelyx, Inc. (ARDX)Join by November 16, 2026Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 16, 2026ARDX - PR Newswire
Uncovering Potential: Penny Stocks To Watch In September 2026 - simplywall.st
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Ardelyx, Inc. (ARDX) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of November 16, 2026 Deadline - ACCESS Newswire
Securities Lawsuit Alert: Ardelyx, Inc. (ARDX)Contact Levi & Korsinsky Before November 16, 2026 - ACCESS Newswire
Investors in Ardelyx, Inc. (ARDX): Protect Your RightsContact Levi & Korsinsky Before November 16, 2026 - ACCESS Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Ardelyx puts lessons from FDA’s Untitled Letters into practice in first Ibsrela TV campaign - Medical Marketing and Media
Class action filed against Ardelyx over misleading growth claims, stock drops 18% after revenue guidance cut. - Pluang
ARDX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ardelyx (A - The National Law Review
Investors in Ardelyx face lawsuit over alleged misleading revenue guidance and stock drop. - Pluang
Class action lawsuit filed against Ardelyx over misleading statements on drug sales and patient access. - Pluang
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit - PR Newswire
Ardelyx Targets $500M Revenue This Year, Profitability by 2027 - TradingView
Investor Alert: Robbins LLP Informs Investors of the Ardelyx, Inc. Class Action Lawsuit - The National Law Review
Ardelyx (ARDX) Stock Still Looks Undervalued After Its 161% Five Year Run - simplywall.st
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits
Ardelyx stock falls 18% after Q2 miss and XPHOZAH target withdrawal - scanx.trade
ARDX SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ardelyx (NASDAQ: ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026 - AOL.ca
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - Carroll County Mirror-Democrat
ARDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ardelyx - GlobeNewswire
ARDX INVESTOR ALERT: Class Action Lawsuit Filed on Behalf - GlobeNewswire
Ardelyx to participate in three major healthcare conferences in September - scanx.trade
Ardelyx Q2FY26 Results: Revenue hits record $118M, IBSRELA guide cut - scanx.trade
Ardelyx Q2 2026 Earnings Call Transcript - Benzinga
Ardelyx, Inc. (ARDX) Stock Analysis: Unveiling a Potential 281% Upside in the Biotech Sector - DirectorsTalk Interviews
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Ardelyx, Inc. Common Stock and Sets a Lead Plaintiff Deadline of November 16, 2026 - GlobeNewswire
Ardelyx at Morgan Stanley conference: growth plan meets payer pressure By Investing.com - Investing.com South Africa
Ardelyx at Morgan Stanley conference: growth plan meets payer pressure - Investing.com
High Growth Tech Stocks in the US for September 2026 - simplywall.st
Ardelyx (ARDX) Could Be 72% Undervalued Following Its September Investor Conference Run - simplywall.st
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug - Stocktwits
Ardelyx at cantor global healthcare conference: growth meets payer pressure - Investing.com
ARDX: Profitability targeted by 2027 as IBSRELA and XPHOZAH drive growth amid payer and market shifts - TradingView
Ardelyx at cantor global healthcare conference: growth meets payer pressure By Investing.com - Investing.com UK
Ardelyx Inc (ARDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ardelyx (ARDX) Has Investors Looking Closer, But What Is Driving The Attention? - simplywall.st
Ardelyx CHRO James Brady sells $58,378 in stock By Investing.com - Investing.com Nigeria
Ardelyx CHRO James Brady sells $58,378 in stock - Investing.com
Ardelyx to Participate in Upcoming Investor Conferences - Yahoo Finance
Have Insiders Sold Ardelyx Shares Recently? - simplywall.st
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):